Abbott Laboratories (ABT)
Glenmede Investment Management LP Has $159.51 Million Stock Holdings in Abbott Laboratories $ABT
Glenmede Investment Management LP lowered its position in shares of Abbott Laboratories (NYSE: ABT) by 4.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,190,887 shares of the healthcare product maker's stock after selling 61,675 shares during the quarter. Abbott Laboratories accounts
Absolute Software Co. (ABT.TO) (TSE:ABT) Stock Price Crosses Above Two Hundred Day Moving Average – Here’s Why
Absolute Software Co. (ABT.TO) (TSE: ABT - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of C$0.00 and traded as high as C$19.29. Absolute Software Co. (ABT.TO) shares last traded at C$19.29, with a volume of 554 shares. Absolute Software Co.
Why Abbott (ABT) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Hope for the Best and Plan for the Worst: The 5 Safest Dividend Aristocrats
The stock market could face serious trouble in 2026 as extreme valuations collide with geopolitical tensions, AI investment skepticism, and policy headwinds.
Abbott (ABT) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Abbott (ABT) Rises Higher Than Market: Key Facts
Abbott (ABT) reached $112.65 at the closing of the latest trading day, reflecting a +2.82% change compared to its last close.
Abbott Laboratories Offers Long-Term Upside Despite Recent Stumbles
Abbott Laboratories (ABT) remains a Buy, with the stock undervalued at $109.56 despite recent execution missteps and Nutrition segment weakness. Core Devices and Diagnostics segments continue to deliver high single-digit sales growth and double-digit EPS growth, supporting the investment thesis. Nutrition remains a key risk, but management expects a turnaround in the second half; Exact Sciences acquisition could add a new high-growth vertical.
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Abbott (ABT) Stock Sinks As Market Gains: Here's Why
Abbott (ABT) closed at $114.12 in the latest trading session, marking a -1.92% move from the prior day.
Abbott (ABT) Ascends While Market Falls: Some Facts to Note
Abbott (ABT) reached $115.29 at the closing of the latest trading day, reflecting a +2.74% change compared to its last close.
Abbott (ABT) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Alliance Wealth Advisors LLC UT Has $2.44 Million Position in Abbott Laboratories $ABT
Alliance Wealth Advisors LLC UT lowered its stake in Abbott Laboratories (NYSE: ABT) by 30.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 18,225 shares of the healthcare product maker's stock after selling 8,086 shares during the quarter. Alliance
